Stock ABBVD ABBVIE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases AbbVie Inc. Buenos Aires S.E.

Equities

ABBVD

ARBCOM4603M9

End-of-day quote Buenos Aires S.E.
Other stock markets
 06:00:00 2024-07-15 pm EDT 		5-day change 1st Jan Change
16.9 USD +0.60% Intraday chart for AbbVie Inc. +2.11% +11.18%
Jul. 12 AbbVie Submits FDA, EMA Applications for Upadacitinib to Treat Giant Cell Arteritis MT
Jul. 12 AbbVie Seeks U.S., Europe OK of Rinvoq in Giant Cell Arteritis DJ

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib in Giant Cell Arteritis
AQ
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis
PR
AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research and Development and Chief Scientific Officer
AQ
AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer
PR
AbbVie : Results of Operations and Financial Condition Form 8 K
PU
AbbVie to Host Second-Quarter 2024 Earnings Conference Call
PR
Robert A. Michael Assumes Role as AbbVie Chief Executive Officer
PR
AbbVie - Introducing Alle Payment Plans, Powered by Cherry
AQ
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
PR
AbbVie Acquires Celsius Therapeutics
PR
AbbVie - U.S. Food and Drug Administration Grants Second Approval for EPKINLY to Treat Patients with Relapsed or Refractory Follicular Lymphoma
AQ
Introducing Allē Payment Plans, Powered by Cherry
PR
U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma
PR
AbbVie Provides U.S. Regulatory Update on ABBV-951
AQ
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)
PR
AbbVie Declares Quarterly Dividend
AQ
AbbVie Declares Quarterly Dividend
PR
AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors
PR
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
PR
AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABBV Stock
  4. ABBVD Stock
  5. News AbbVie Inc.
  6. Press Releases